Epizyme Inc. (NASDAQ:EPZM) hit a new 52-week low during trading on Wednesday . The stock traded as low as $7.14 and last traded at $7.33, with a volume of 153,547 shares traded. The stock had previously closed at $7.58.

Several brokerages have commented on EPZM. Leerink Swann restated an “outperform” rating and set a $39.00 target price on shares of Epizyme in a research report on Tuesday, June 21st. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Mizuho reiterated a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research report on Monday, June 20th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 price objective on shares of Epizyme in a research report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.11.

The stock’s 50-day moving average price is $9.21 and its 200-day moving average price is $10.35. The stock’s market cap is $422.79 million.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. Equities research analysts predict that Epizyme Inc. will post ($2.19) earnings per share for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total value of $40,120.00. Following the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in Epizyme stock. Jennison Associates LLC raised its position in shares of Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned 2.14% of Epizyme worth $14,320,000 at the end of the most recent reporting period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.